St. Jude revisits RESPECT trial, touts signs of benefits of Amplatzer device

February 8, 2013 by MassDevice staff

St. Jude Medical touts new findings from its failed RESPECT trial, reporting that the Amplatzer PFO closure device demonstrated benefits over drug therapy alone.

St. Jude Medical logo

Medical device giant St. Jude Medical (NYSE:STJ) resurrected data from its failed RESPECT study, touting additional analyses and benefits of its Amplatzer patent foramen ovale closure device.

St. Jude took a hit last year when the RESPECT trial failed to meet its clinical endpoints, but the company wasn't about to stop there.

Sign up to get our free newsletters delivered right to your inbox.

The trial concluded that the Amplatzer heart implant failed to significantly reduce cryptogenic stroke compared with standard treatment with drugs, sending STJ shares sinking on Wall Street and putting fellow PFO closure devices makers on the defensive.

At this year's International Stroke Conference 2013 in Honolulu St. Jude revisited the RESPECT trial, touting new findings that patients with the Amplatzer device had fewer and smaller strokes than patients who received drug therapy alone.

The results demonstrate that PFO closure may still be the right treatment for the right patients.